Page 1690 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 115

REFERENCES

1. UNOS. United Network for Organ Sharing: 2002 Annual 12. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associ-
Report of the U.S. Organ Procurement and Transplantation ated with sirolimus therapy in renal-transplant recipients.
Network and the Scientific Registry of Transplant Recipients. N Engl J Med. 2000;343(3):225-226.
Transplant Data 1992–2001, Rockville, MD, Department of 13. Morelon E, Stern M, Israël-Biet D, et al. Characteristics of
Health and Human Services/Health Resources and Services sirolimus-associated interstitial pneumonitis in renal transplant
Administration/Office of Special Programs/Division of patients. Transplantation. 2001;72:787.
Transplantation. 2002:1.
14. Henry M, Newsteadm C. Sirolimus: another cause of
2. Eason J, Nair S, Cohen A, Blazek J, Loss GJ. Steroid-free liver drug-induced interstitial pneumonitis. Transplantation.
transplantation using rabbit antithymocyte globulin and early 2001;72(5):773-774.
tacrolimus monotherapy. Transplantation. 2003;75:1396.
15. Lennon A, Finan K, FitzGerald M, McCormick P. Interstitial
3. Kahan B. Cyclosporine. N Engl J Med. 1989;321(25):1725-1738. pneumonitis associated with sirolimus (rapamycin) therapy
4. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclospo- after liver transplantation. Transplantation. 2001;72:1166.
rine levels (Cmax) correlate with freedom from liver graft 16. King-Biggs M, Dunitz J, Park S, Kay Savik S, Hertz M.
rejection: results of a prospective, randomized comparison of Airway anastomotic dehiscence associated with use of siroli-
Neoral and Sandimmune for liver transplantation (NOF-8). mus immediately after lung transplantation. Transplantation.
Transplantation. 1999;67:1133. 2003;75:1437.
5. Gummert J, Ikonen T, Morris R. Newer immunosuppressive 17. Warning regarding bronchial anastomotic dehiscence including
drugs: a review. J Am Soc Nephrol. 1999;10(6):1366-1380. fatal cases. Letter from Wyeth Medical Affairs to Health Care
6. European FK506 Multicentre Liver Study Group. A comparison Providers. 2003.
of tacrolimus (FK 506) and cyclosporine for immunosuppres- 18. Meier-Kriesche H, Steffen B, Hochberg A, et al. Long-term use
sion in liver transplantation. N Engl J Med. 1994;331:1110. of mycophenolate mofetil is associated with a reduction in the
7. Mayer A, Dmitrewski J, Squifflet J, et al. Multicenter random- incidence and risk of late rejection. Am J Transplant. 2003;3:68.
ized trial comparing tacrolimus (FK506) and cyclosporine in the 19. Ortho Multicenter Transplant Study Group. A randomized
prevention of renal allograft rejection: a report of the European clinical trial of OKT3 monoclonal antibody for acute rejection
Tacrolimus Multi-center Renal Study Group. Transplantation. of cadaveric renal transplants. N Engl J Med. 1985;313:337.
1997;64:436. 20. Chatenoud L, Ferran C, Bach J. The anti-CD3-induced syn-
8. First M, Gerber D, Hariharan S, Kaufman D, Shapiro R. drome: a consequence of massive in vivo cell activation. Curr
Posttransplant diabetes mellitus in kidney allograft recipi- Top Microbiol Immunol. 1991;174:121-134.
ents: incidence, risk factors, and management. Transplantation. 21. Dmitrewski J, Krentz A, Mayer A, et al. Metabolic and
2002;73(3):379-386. hormonal effects of tacrolimus (FK506) or cyclosporin immu-
9. Ericzon B, Groth C, Bismuth H, et al. Glucose metabolism nosuppression following renal transplantation. Diabetes Obes
in liver transplant recipients treated with FK 506 or cyclo- Metab. 2001;3(4):287-292.
sporin in the European multicentre study. Transpl Int. 1994; 22. Yoshida E, Buczkowski A, Sirrs S, et al. Post-transplant diabetic
7(suppl 1):S11. ketoacidosis—a possible consequence of immunosuppression
10. Artz M, Boots J, Ligtenberg G, et al. Improved cardiovascular with calcineurin inhibiting agents: a case series. Transpl Int.
risk profile and renal function in renal transplant patients after 2000;13:69.
randomized conversion from cyclosporine to tacrolimus. J Am 23. Polastri L, Galbiati F, Bertuzzi F, et al. Secretory defects induced
Soc Nephrol. 2003;14(7):1880-1888. by immunosuppressive agents on human pancreatic beta-cells.
11. Liver transplantation—excess mortality, graft loss, and hepatic Acta Diabetologica. 2002;39:229.
artery thrombosis (HAT) with sirolimus. Letter from Wyeth to 24. Fuhrer D, Kobayashi M, Jiang H. Insulin release and suppres-
the U.S. Food and Drug Association. 2002. sion by tacrolimus, rapamycin and cyclosporin A are through

Section10-O-Ref.indd 1 1/21/2015 11:30:09 AM